- Home
- TWST
as 10-22-2025 3:52pm EST
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.3B | IPO Year: | 2018 |
| Target Price: | $48.56 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.07 - $55.33 | Next Earning Date: | 11-17-2025 |
| Revenue: | $362,273,000 | Revenue Growth: | 22.72% |
| Revenue Growth (this year): | 22.11% | Revenue Growth (next year): | 17.50% |
Stock Insider Trading Activity of Twist Bioscience Corporation (TWST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Laponis Adam | TWST | Chief Financial Officer | Oct 9 '25 | Sell | $32.92 | 2,517 | $82,864.67 | 91,525 | |
| Laponis Adam | TWST | Chief Financial Officer | Oct 8 '25 | Sell | $31.15 | 3,000 | $93,450.00 | 91,525 | |
| Leproust Emily M. | TWST | Chief Executive Officer | Oct 6 '25 | Sell | $32.19 | 31,348 | $1,008,998.08 | 601,212 | |
| Green Paula | TWST | SVP of Human Resources | Oct 6 '25 | Sell | $32.19 | 9,724 | $312,986.39 | 114,678 | |
| Cho Dennis | TWST | See Remarks | Oct 6 '25 | Sell | $32.19 | 3,876 | $124,756.81 | 98,710 | |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | Oct 6 '25 | Sell | $32.19 | 2,041 | $65,693.67 | 46,413 | |
| Finn Patrick John | TWST | President and COO | Oct 6 '25 | Sell | $32.19 | 23,747 | $764,344.69 | 208,735 | |
| Laponis Adam | TWST | Chief Financial Officer | Oct 6 '25 | Sell | $32.19 | 5,875 | $189,098.63 | 91,525 | |
| Leproust Emily M. | TWST | Chief Executive Officer | Oct 2 '25 | Sell | $29.16 | 476 | $13,880.64 | 601,212 | |
| Green Paula | TWST | SVP of Human Resources | Oct 2 '25 | Sell | $29.16 | 140 | $4,082.54 | 114,678 |
Latest Twist Bioscience Corporation News
TWST Breaking Stock News: Dive into TWST Ticker-Specific Updates for Smart Investing
Business Wire
17 days ago
Twist Bioscience and Element Biosciences Advance Collaboration with Launch of New Trinity Freestyle™ Sequencing Workflow for the AVITI™ System
Business Wire
20 days ago
Twist Bioscience Announces Publication in Science Examining Biosecurity Screening Practices in AI-assisted Protein Design
Insider Monkey
4 months ago
Twist and Element Biosciences Expands Pact for Sequencing Workflow Solutions
Simply Wall St.
4 months ago
Here's Why We're Not At All Concerned With Twist Bioscience's (NASDAQ:TWST) Cash Burn Situation
MT Newswires
5 months ago
Twist Bioscience Expands Element Biosciences Partnership for End-to-End NGS Tools
Business Wire
5 months ago
Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions
Business Wire
5 months ago
Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference
Business Wire
5 months ago
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Compare TWST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TWST Twist Bioscience Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.